COGT - CIK 0001622229
The table below shows Cogent Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$264.44M | -$207.79M | -$153.62M | -$118.64M | -$58.76M | -$35.85M |
| Capital expenditure | $1.55M | $573.00K | $2.80M | $6.86M | $1.72M | - |
| Investing cash flow | -$399.53M | $38.28M | -$97.82M | -$124.72M | -$1.72M | $8.42M |
| Dividends paid | - | - | - | - | - |
Cogent Biosciences, Inc. reported operating cash flow of -$264.44M for fiscal year 2025. That is down 27.3% from -$207.79M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$25.84M (FY 2017) to -$264.44M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $878.23M | $214.45M | $163.54M | $163.56M | $37.98M | $232.20M |